Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Trastuzumab deruxtecan

4

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

2
Last update : 15/08/2022
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Trastuzumab
5
Trastuzumab emtansine (Ado-trastuzumab emtansine - TDM-1)
1

Publications

Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients.
ESMO open 2023 Dec;8;102043 2023 Dec
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
The New England journal of medicine 2022 Mar 24;386;1143-1154 2022 Mar 24
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
Drugs 2022 Jun;82;979-987 2022 Jun
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
ESMO open 2022 Aug;7;100554 2022 Aug
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
The New England journal of medicine 2020 Feb 13;382;610-621 2020 Feb 13
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
The Lancet. Oncology 2019 Jun;20;816-826 2019 Jun
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
The Lancet. Oncology 2019 Jun;20;827-836 2019 Jun

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies